% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Weiss:284423,
      author       = {L. Weiss and V. Heinemann$^*$ and L. E. Fischer and F.
                      Gieseler and T. Hoehler and J. Mayerle and D. Quietzsch and
                      A. Reinacher-Schick and M. Schenk and G. Seipelt and J.
                      Siveke$^*$ and M. Stahl and U. Vehling-Kaiser and D. T.
                      Waldschmidt and K. Dorman$^*$ and D. Zhang$^*$ and C. B.
                      Westphalen and M. von Bergwelt-Baildon$^*$ and S. Boeck$^*$
                      and M. Haas},
      title        = {{T}hree-month life expectancy as inclusion criterion for
                      clinical trials in advanced pancreatic cancer: is it really
                      a valid tool for patient selection?},
      journal      = {Clinical and translational oncology},
      volume       = {26},
      number       = {5},
      issn         = {1699-048X},
      address      = {Mailand},
      publisher    = {Springer Milan},
      reportid     = {DKFZ-2023-02012},
      pages        = {1268-1272},
      year         = {2024},
      note         = {2024 May;26(5):1268-1272},
      abstract     = {To analyze the 3-month life expectancy rate in pancreatic
                      cancer (PC) patients treated within prospective trials from
                      the German AIO study group.A pooled analysis was conducted
                      for patients with advanced PC that were treated within five
                      phase II/III studies conducted between 1997 and 2017
                      (Gem/Cis, Ro96, RC57, ACCEPT, RASH). The primary goal for
                      the current report was to identify the actual 3-month
                      survival rate, a standard inclusion criterion in oncology
                      trials.Overall, 912 patients were included, $83\%$ had
                      metastatic and $17\%$ locally advanced PC; the estimated
                      median overall survival (OS) was 7.1 months. Twenty-one
                      percent of the participants survived < 3 months, with a
                      range from $26\%$ in RC57 to $15\%$ in RASH. Significant
                      predictors for not reaching 3-month OS were > 1 previous
                      treatment line (p < 0.001) and performance status (p <
                      0.001).Despite the definition of a life expectancy of > 3
                      months as a standard inclusion criterion in clinical trials
                      for advanced PC, a significant proportion of study patients
                      does not survive > 3 months.NCT00440167 (AIO-PK0104),
                      NCT01729481 (RASH), NCT01728818 (ACCEPT).},
      keywords     = {Clinical trial (Other) / Inclusion criterion (Other) /
                      Pancreatic cancer (Other) / Prognosis (Other)},
      cin          = {MU01 / ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331 / I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37794220},
      doi          = {10.1007/s12094-023-03323-1},
      url          = {https://inrepo02.dkfz.de/record/284423},
}